AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%，引起了市场的广泛关注。
消息面上，该公司于周五正式登陆美股市场，但新股表现不佳，开盘即大幅下跌。根据相关报道，其IPO价格为16美元，上市后股价持续走低，市场对其首秀反应冷淡。
AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司，专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元，其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。
AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%，引起了市场的广泛关注。
消息面上，该公司于周五正式登陆美股市场，但新股表现不佳，开盘即大幅下跌。根据相关报道，其IPO价格为16美元，上市后股价持续走低，市场对其首秀反应冷淡。
AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司，专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元，其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.